The pathogenesis of choroidal neovascularization in patients with age-related macular degeneration.

Peter A Campochiaro, P. Soloway, S. J. Ryan, J. W. Miller

Research output: Contribution to journalArticle

Abstract

Laser photocoagulation and several experimental treatments for choroidal neovascularization (CNV) in patients with age-related macular degeneration attempt to ablate the neovascularization, but do not address underlying angiogenic stimuli. As a result, recurrences are a major problem. Drug treatment to counter the growth of CNV would be a major advance, but its development is impeded by lack of knowledge concerning the stimuli and other molecular signals involved in the pathogenesis of CNV. Herein we explore clues that can be gleaned from clinical, epidemiological, pathological, and experimental data. These suggest that abnormalities of the extracellular matrix of retinal pigmented epithelial (RPE) cells may promote a pro-angiogenic RPE phenotype that contributes to the development of CNV. This provides a general hypothesis that can be tested, but it is also necessary to test hypotheses regarding the specific alterations in gene expression that contribute to CNV. Identification of alterations in gene expression will provide targets for rational design of drug treatment.

Original languageEnglish (US)
Pages (from-to)34
Number of pages1
JournalMolecular Vision
Volume5
StatePublished - Nov 3 1999

Fingerprint

Choroidal Neovascularization
Macular Degeneration
Gene Expression
Light Coagulation
Drug Design
Extracellular Matrix
Lasers
Therapeutics
Epithelial Cells
Phenotype
Recurrence
Growth
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Ophthalmology

Cite this

The pathogenesis of choroidal neovascularization in patients with age-related macular degeneration. / Campochiaro, Peter A; Soloway, P.; Ryan, S. J.; Miller, J. W.

In: Molecular Vision, Vol. 5, 03.11.1999, p. 34.

Research output: Contribution to journalArticle

@article{0b262dfaa75e451c9b13507a77b76bbd,
title = "The pathogenesis of choroidal neovascularization in patients with age-related macular degeneration.",
abstract = "Laser photocoagulation and several experimental treatments for choroidal neovascularization (CNV) in patients with age-related macular degeneration attempt to ablate the neovascularization, but do not address underlying angiogenic stimuli. As a result, recurrences are a major problem. Drug treatment to counter the growth of CNV would be a major advance, but its development is impeded by lack of knowledge concerning the stimuli and other molecular signals involved in the pathogenesis of CNV. Herein we explore clues that can be gleaned from clinical, epidemiological, pathological, and experimental data. These suggest that abnormalities of the extracellular matrix of retinal pigmented epithelial (RPE) cells may promote a pro-angiogenic RPE phenotype that contributes to the development of CNV. This provides a general hypothesis that can be tested, but it is also necessary to test hypotheses regarding the specific alterations in gene expression that contribute to CNV. Identification of alterations in gene expression will provide targets for rational design of drug treatment.",
author = "Campochiaro, {Peter A} and P. Soloway and Ryan, {S. J.} and Miller, {J. W.}",
year = "1999",
month = "11",
day = "3",
language = "English (US)",
volume = "5",
pages = "34",
journal = "Molecular Vision",
issn = "1090-0535",

}

TY - JOUR

T1 - The pathogenesis of choroidal neovascularization in patients with age-related macular degeneration.

AU - Campochiaro, Peter A

AU - Soloway, P.

AU - Ryan, S. J.

AU - Miller, J. W.

PY - 1999/11/3

Y1 - 1999/11/3

N2 - Laser photocoagulation and several experimental treatments for choroidal neovascularization (CNV) in patients with age-related macular degeneration attempt to ablate the neovascularization, but do not address underlying angiogenic stimuli. As a result, recurrences are a major problem. Drug treatment to counter the growth of CNV would be a major advance, but its development is impeded by lack of knowledge concerning the stimuli and other molecular signals involved in the pathogenesis of CNV. Herein we explore clues that can be gleaned from clinical, epidemiological, pathological, and experimental data. These suggest that abnormalities of the extracellular matrix of retinal pigmented epithelial (RPE) cells may promote a pro-angiogenic RPE phenotype that contributes to the development of CNV. This provides a general hypothesis that can be tested, but it is also necessary to test hypotheses regarding the specific alterations in gene expression that contribute to CNV. Identification of alterations in gene expression will provide targets for rational design of drug treatment.

AB - Laser photocoagulation and several experimental treatments for choroidal neovascularization (CNV) in patients with age-related macular degeneration attempt to ablate the neovascularization, but do not address underlying angiogenic stimuli. As a result, recurrences are a major problem. Drug treatment to counter the growth of CNV would be a major advance, but its development is impeded by lack of knowledge concerning the stimuli and other molecular signals involved in the pathogenesis of CNV. Herein we explore clues that can be gleaned from clinical, epidemiological, pathological, and experimental data. These suggest that abnormalities of the extracellular matrix of retinal pigmented epithelial (RPE) cells may promote a pro-angiogenic RPE phenotype that contributes to the development of CNV. This provides a general hypothesis that can be tested, but it is also necessary to test hypotheses regarding the specific alterations in gene expression that contribute to CNV. Identification of alterations in gene expression will provide targets for rational design of drug treatment.

UR - http://www.scopus.com/inward/record.url?scp=0033520648&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033520648&partnerID=8YFLogxK

M3 - Article

C2 - 10562658

AN - SCOPUS:0033520648

VL - 5

SP - 34

JO - Molecular Vision

JF - Molecular Vision

SN - 1090-0535

ER -